121
Views
6
CrossRef citations to date
0
Altmetric
Reviews

Design and in silico screening of inhibitors of the cholera toxin

Pages 923-938 | Published online: 20 Aug 2009
 

Abstract

Background: Cholera toxin (CT) is the causative agent for cholera, which is responsible for the death of millions of people. The holotoxin structure of CT in conjunction with its mechanism of action reveals four potential target areas to design CT therapeutic agents: i) the inhibition of adenylate cyclase; ii) the blockage of the active site of the enzyme located in the A subunit; iii) the disruption of the assembly of the holotoxin by interrupting the A2–B interaction; and iv) the interception of the receptor binding to the bottom of the B pentamer. Objective/method: In this review, some of the most exciting and successful CT inhibitors and their design strategies are highlighted. These include transition state analogues and substrate analogues as CTA inhibitors, and pentavalent ligand, sugar-containing dendrimers and sugar mimics as CTB inhibitors. Some recent progress in in silico screening methods is also summarized. Conclusion: The most potent inhibitor demonstrated an IC50 of 50 pM.

Acknowledgements

The author thanks E Fan and W Hol for their discussions on the inhibitor design of cholera toxin, C Verlinde for discussions on computer modeling, and N Angelo for proofreading this manuscript.

Notes

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.